TEVAR 2016: Companies Push New Frontiers In Thoracic Aortic Interventions
Although thoracic endovascular aortic repair (TEVAR) is now routine for lesions like dissection of the descending aorta, the Big Three aortic endovascular companies are developing devices for the more technically challenging proximal and distal portions of the thoracic aorta while physicians refine TEVAR in the descending aorta. Insiders say endovascular techniques are overcoming limitations and physicians will soon be able to treat the entire aorta, from the aortic valve to the bifurcation.
You may also be interested in...
As endovascular aortic repair (EVAR) becomes a mainstream procedure, companies are racing to develop products that can treat patients with more challenging anatomy. As the space bubbles with ongoing trials and new-product launches, newer companies hope to make their mark in a space dominated by the established market leaders Medtronic PLC, Cook Medical Inc. and WL Gore & Associates.
BMS CEO Boerner made predictions of AI being a game changer for R&D in India come true with plans to conduct AI-driven small molecule drug research in India, set to house the company’s largest R&D site outside of the US by next year. He also spoke of bringing its drugs to treat multiple sclerosis and Lupus to the country
When does an app qualify as a medical device and when does it not? A German court case appears to have wider-reaching implications for medtech than might first appear.